Inceptionr LLC Acquires Shares of 7,218 Tarsus Pharmaceuticals, Inc. $TARS

Inceptionr LLC purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the third quarter, HoldingsChannel.com reports. The fund purchased 7,218 shares of the company’s stock, valued at approximately $429,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TARS. Osaic Holdings Inc. increased its position in Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Tarsus Pharmaceuticals by 220.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after acquiring an additional 2,782 shares during the last quarter. West Wealth Group LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the third quarter worth $202,000. Valeo Financial Advisors LLC bought a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at $209,000. Finally, XTX Topco Ltd bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at $227,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Insiders Place Their Bets

In related news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the sale, the insider owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 8.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TARS. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Mizuho started coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Trading Down 4.3%

Tarsus Pharmaceuticals stock opened at $69.88 on Thursday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The business has a 50-day simple moving average of $70.74 and a two-hundred day simple moving average of $69.83. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The company has a market cap of $2.97 billion, a P/E ratio of -43.14 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.